Gå frakoblet med Player FM -appen!
John LaMattina – Drug Price Controls and IP Attacks Get Real
Manage episode 409132472 series 2401268
John LaMattina was President of Pfizer Global Research and Development and ran an international team of over 13,000 scientists and professionals. He has authored several books, including the highly acclaimed Pharma and Profits – Balancing Innovation, Medicine, and Drug Prices. He is also a senior partner at PureTech Health and a contributor to Forbes.
Last year, when John was a guest on the Vital Health Podcast, the potential impacts of the Inflation Reduction Act (IRA) were still theoretical. But one year on, the Centers for Medicare and Medicaid Services (CMS) released their prices for drug negotiations, and the impacts of the IRA have now become real. John discusses how the IRA will impact the development of critically needed new therapies and provides his insights into the Biden Administration’s recent threats to use march-in rights to confiscate intellectual property as a way to control the price of drugs.
See omnystudio.com/listener for privacy information.
101 episoder
Manage episode 409132472 series 2401268
John LaMattina was President of Pfizer Global Research and Development and ran an international team of over 13,000 scientists and professionals. He has authored several books, including the highly acclaimed Pharma and Profits – Balancing Innovation, Medicine, and Drug Prices. He is also a senior partner at PureTech Health and a contributor to Forbes.
Last year, when John was a guest on the Vital Health Podcast, the potential impacts of the Inflation Reduction Act (IRA) were still theoretical. But one year on, the Centers for Medicare and Medicaid Services (CMS) released their prices for drug negotiations, and the impacts of the IRA have now become real. John discusses how the IRA will impact the development of critically needed new therapies and provides his insights into the Biden Administration’s recent threats to use march-in rights to confiscate intellectual property as a way to control the price of drugs.
See omnystudio.com/listener for privacy information.
101 episoder
Alle episoder
×1 Breaking Barriers: The Prime Rose Project and Off-Label Drug Innovations 29:15
1 Impact of the Inflation Reduction Act on Venture Capital in Life Sciences 36:11
1 Investing in Health: Pathways to a Well-being Economy and Smarter Healthcare Budgets 35:30
1 Addressing Europe's Health Challenges: Innovation, Prevention, and Policy 38:30
1 The Future of Biotech: Steve Potts on Innovation, Policy, and the Impact of the IRA 24:58
1 Revolutionizing Healthcare with Real-World Data 27:13
1 Exploring the Intersection of Intellectual Property and Biotech Innovation 56:52
1 Unlocking the Power of Genomic Data: NashBIO's Role in Healthcare Innovation 19:00
1 MEP Pernille Weiss – Rapporteur of the EU GPL 47:33
1 Transforming Health Communications: Insights from Virginia Amann 26:51
1 Joe Panetta – Policy Impacts on California Biopharma 27:30
1 Niklas Blomberg, Executive Director, EU Innovative Health Initiative 19:58
1 Congressman Michael Burgess – IRA and March-in Rights 28:55
1 Kim Hawkins - Project Co-Lead of IMI’s Trials@Home 32:51
1 Douglas Holtz-Eakin, “Indications are going to be deeply affected by the IRA” 54:59
Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.